Beauty Health (NASDAQ:SKIN – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Risk & Volatility
Beauty Health has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
Insider & Institutional Ownership
93.3% of Beauty Health shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 41.0% of Beauty Health shares are owned by company insiders. Comparatively, 8.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Beauty Health | -8.11% | -44.83% | -3.54% |
| Lucid Diagnostics | -1,069.87% | N/A | -123.54% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Beauty Health and Lucid Diagnostics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beauty Health | 1 | 3 | 1 | 0 | 2.00 |
| Lucid Diagnostics | 0 | 0 | 4 | 1 | 3.20 |
Beauty Health currently has a consensus price target of $2.50, indicating a potential upside of 89.39%. Lucid Diagnostics has a consensus price target of $3.63, indicating a potential upside of 141.67%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Beauty Health.
Valuation & Earnings
This table compares Beauty Health and Lucid Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beauty Health | $334.29 million | 0.49 | -$100.12 million | ($0.43) | -3.07 |
| Lucid Diagnostics | $4.19 million | 21.25 | -$52.67 million | ($1.14) | -1.32 |
Lucid Diagnostics has lower revenue, but higher earnings than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Lucid Diagnostics beats Beauty Health on 9 of the 15 factors compared between the two stocks.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
